Clinical trial · Observational
Primary Mediastinal Large B-cell Lymphoma (PMBCL): Multicenter Retrospective Study
Primary Mediastinal Large B-cell Lymphoma (PMBCL): Multicenter Retrospective Study by the Fondazione Italiana Linfomi.
NCT05162170CI-TRIAL-00113047completedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The present study consists of a retrospective multicentric collection of all consecutive patients with PMBCL diagnosed over the time period considered (13 years, from 2007 to 2019 inclusive).
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Primary Mediastinal Large B-cell Lymphoma (PMBCL) | Primary Mediastinal Large B-Cell Lymphoma | ONTOLOGY_EXACT | 0.85 |
Interventions
Interventions (0)
Data not yet available
No intervention recorded.
Design
Arms and outcomes
Arms (1)
- label
- Primary Mediastinal large B-Cell Lymphoma (PMBCL)
- description
- The present study consists of a retrospective multicenter collection of series of consecutive patients diagnosed with PMBCL over the relevant time period (13 years, from 2007 to 2019 included).
Primary outcomes (6)
- measure
- Rate of primary/early refractory disease
- timeFrame
- The endpoint will be evaluated from the beginning to the end of the study (up to 24 months)
- description
- The study aims to evaluate the rate of primary/early refractory disease (Primary mediastinal large B-cell lymphoma)
- measure
- Overall response rate (ORR)
- timeFrame
- The endpoint will be evaluated from the beginning to the end of the study (up to 24 months)
- description
- Overall Response Rate is defined as the percentage of patients in complete remission or in partial remission
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * All consecutive patients treated in the centre during the period considered * Age\>=18 years * Histological diagnosis of PMBCL * Signature of "Informed Consent" to participate in the study (if applicable) * Treatment according to local practice * Diagnosis between 01 January 2007 and 31 December 2019 Exclusion Criteria: \- The exclusion criteria, being an observational study, are focused and limited to excluding cases with a non-compliant histological diagnosis.
References
Publications (0)
Data not yet available
No reference posted for this study.